evaluation of the efficacy and the cutaneous acceptability of a dermocosmetic product in the repigmentation of vitiligo

Conditions: Vitiligo

Summary: * study in proof of concept; * double blind study; * comparative study, versus placebo in intra-individual * three parallel groups testing different dosages / combinations of treatments * randomized.

this study has as objectives: primary objective : • evaluate the percentage of repigmentation observed one month after the end of three months of treatment measured on an objective layer by image analysis; secondary objectives: evaluate: * the percentage of repigmentation observed after one, two and three months of treatment measured on an objective layer by image analysis; * the ability of the product to maintain the human body in good condition (cutaneous acceptability) by clinical examination by the dermatologist; * patient satisfaction using a visual analogue scale from 0 to 10. * the illustrative effect using standardized photographs; * the quantity of product by weighing the tubes. * the occurrence of possible adverse effects. population: * sexe: female and male; * age: over 18 years old; * patients with stable non-segmental vitiligo lesions (defined as no new lesions or lesions that have been present for at least 3 months, lack of hypochromic margins in wood's lumen and absence of confetti depigmentation); * patients with 2 to 6 symmetrical lesions (1 to 3 on each side). these lesions (macules) will be treated for a minimum surface of 2 cm² and a maximum surface of 100 cm².

Eligibility criteria:
•inclusion criteria: sexe: female and male; * age: over 18 years old; * patients with stable non-segmental vitiligo lesions (defined as no new lesions or lesions that have been present for at least 3 months, lack of hypochromic margins in wood's lumen and absence of confetti depigmentation); * patients with 2 to 6 symmetrical lesions (1 to 3 on each side). these lesions (macules) will be treated for a minimum surface of 2 cm² and a maximum surface of 100 cm². * healthy volunteer; * volunteer having given in writing his free, informed and express consent; * volunteer willing to abide by the protocol and procedures of the study. exclusion criteria: * pregnant woman or woman who is breastfeeding or planning for early pregnancy during the study; * patient with segmental or mixed vitiligo; * patient with vitiligo of the external genitalia; * patient with vitiligo touching hands and feet only * patient with a history of skin cancer or pre-cancerous skin lesions; * patient taking topical or systemic vitiligo treatments in the month prior to the start of the study; * patient taking concomitant local or general corticosteroid therapy or immunomodulatory therapy; * patient with a history of photodermatoses or taking photosensitizing medications; * patient having planned to expose himself (artificial sun or uv) during the study at the level of the zones to be treated and / or having been exposed during the month preceding the beginning of the study and having an acquired pigmentation (tanning) obvious; * patient who had been treated with phototherapy within 4 weeks before randomization; * patient with lithium allergy.